CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC.

@article{Seidman2004CALGB9P,
  title={CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC.},
  author={Andrew David Seidman and Donald A. Berry and Constance T. Cirrincione and Lyndsay A Harris and Lynn G. Dressler and Hyman Bernard Muss and Larry Norton and Eric P. Winer and Clifford A. Hudis},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={512}
}
512 Background: W P is active, well tolerated and feasible with high efficacy alone or with T (Seidman et al. JCO 1998 and 2001). The primary aims of this trial were to determine whether: 1) W P improves response rate (RR) vs. S P, regardless of HER2 status and assignment to T, and 2) T added to P improves RR vs. P alone for HER2 normal tumors. Secondary objectives were to evaluate time to progression (TTP) and overall survival (OS) with respect to the above comparisons. METHODS Patients (pts… CONTINUE READING
67 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

Similar Papers

Loading similar papers…